StockWatch
·
PCBL LTD · QQ2 FY-2027 · THE CALL

Growth credible, but margin compression and Aquapharm miss signal execution risk

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsPCBLPCBL Ltd06 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

EBITDA/tonne improvement guidance on track. Aquapharm ₹75 Cr quarterly target formally deferred; no new target given. Volume guidance softened from 'high single-digit' to 'challenging.'

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

YoY growth credible (14% revenue, 20% PAT) and pricing discipline proven. But -52% QoQ PAT collapse, Aquapharm shortfall (₹42 Cr EBITDA vs ₹75 Cr prior), and export pullback signal weakening demand and execution risk. Long-term structural tailwinds (tyre expansion, battery materials) are real but require flawless H2 delivery and margin stabilization.

₹2474.4 Cr

Revenue · +14.4% YoY

₹74.1 Cr

Reported PAT · +20.2% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Consolidated revenue grew 14% YoY

MET

₹2,474.4 Cr, +14.4% YoY; flat QoQ reveals weak Q1

Profit after tax grew 20% YoY

MET

₹74.1 Cr, +20.2% YoY but -52.1% QoQ; sequential collapse concerning

EBITDA grew 12% YoY to ₹310 Cr

MET

₹310 Cr reported; 12% YoY growth claimed; no contradiction

Aquapharm double-digit growth H2 FY27

MISS

Q2 EBITDA ₹42 Cr; prior ₹75 Cr quarterly target abandoned, not reiterated

Export volume recovery on track

OVERSTATED

Exports -18% QoQ; pulled back deliberately due to margin pressure and customer caution

Earnings quality

What changed since the last call

Deltas vs. the prior call

Aquapharm EBITDA guidance

Withdrawn

Prior ₹75 Cr quarterly EBITDA target deferred by new CEO. Q2 delivered ₹42 Cr; H2 now guided as 'double-digit growth' only

Volume growth outlook

Downgrade

Was 'high single-digit weighted to H2'; now labeled 'challenging' by management. Export pullback -18% QoQ

EBITDA/tonne guidance

Neutral

Reaffirmed double-digit improvement vs FY26 avg (₹16,500-17,000/tonne base). Tracking as expected; no change

Pricing posture

Upgrade

Management emphasizing 'pricing discipline and margin focus' over volume chasing. Spot prices expected higher Nov-Dec

The Q&A

Analysts pressed hard on export volume miss, Aquapharm target abandonment, and softened volume guidance. Management held firm on strategy (disciplined margins over volume) but gave limited H2 recovery path detail. Candid on challenges, not evasive.

The exchanges that mattered

Inventory destocking — Rohit Sinha, Sundhi Securities

Answered

Crude fell to $70, customers reduced stock; now at $110. Customers in wait-and-watch; gradual not sharp buildup expected.

Cost program scale — Sailesh Raja, 360 ONE Capital

Answered

Mostly fixed cost (volume-linked). Structural ~₹10-15 Cr. Acceleration via yield and throughput initiatives in coming quarters.

Export volume forecast — Sailesh Raja, 360 ONE Capital

Partial

Pulled back due to low margins in Southeast Asia. U.S./Europe infrastructure setup will unlock growth next year.

Specialty Carbon Black — Sailesh Raja, 360 ONE Capital

Partial

Line 6 commercialized, Mundra Line coming. Feedstock is the constraint. Significant growth expected as sourcing improves.

Aquapharm growth drivers — Aditya Khetan, SMIFS

Answered

Driven by volume (new products: PBTC, GLDA) plus pricing. HEDP duty impact TBD; working on finalization.

Antidumping duty — Aditya Khetan, SMIFS

Partial

Provisional now; finalizing. No specific numbers in forecast yet. Will help both margin and volume.

Raw material sourcing — Aditya Khetan, SMIFS

Partial

Diversifying to U.S., Korea, Malaysia, Thailand. Quality and yield must match. Premium 1-2% on Southeast Asia.

Volume growth guidance — Aditya Khetan, SMIFS

Answered

That's challenging now. Macro headwinds and customer caution. EBITDA/tonne guidance continues.

Carbon Black spread dynamics — Harsh Motika, SKP Securities

Answered

Spread ~₹17,500/tonne net EBITDA this quarter. Russia supply tightness and China cost inflation should support H2.

Battery materials timeline — Harsh Motika, SKP Securities

Partial

Silicon carbon composite in internal trials. Not graphite yet. Trials progressing Palej, Belgium, Australia sites.

Guidance

Forward guidance and management's confidence

FY27 double-digit revenue growth

Medium

14.4% YoY Q2 sets pace for 12%+ FY27 if H2 stable. Dependent on inventory normalization and macro

Carbon Black domestic high single-digit; export recovery FY28

Low

Export volumes down; recovery now pushed to next year due to tariff, macro uncertainty

Aquapharm FY27 double-digit revenue growth

Low

Q2 ₹433 Cr; prior ₹75 Cr quarterly EBITDA target abandoned. H2 growth dependent on new product uptake

EBITDA/tonne: double-digit improvement over FY26 avg (₹16,500-17,000/tonne)

High

Reaffirmed on call. Current run-rate ₹17,500/tonne implies ~6% improvement. On track

Operating margin: pricing discipline focus, volume secondary

Medium

NPM 3.0% suggests significant tax/interest burden. Margin profile softer than headline growth implies

FY27 capex ~₹300 Cr; Specialty CB Line 6 done, Mundra Line in progress

Medium

Coal tar plant finalization ongoing. Depends on supplier contracts (almost finalized)

Risks the call surfaced

Ranked by how much they should concern a holder

Geopolitical & tariff

Medium

U.S.-India tariff negotiations ongoing. Russia CBFS supply disruptions impacting global flows. Customers delaying sourcing decisions.

Volume & demand

Medium

Customers maintaining lean inventory due to crude price uncertainty. Volume guidance softer than prior. Export pullback deliberate.

Aquapharm execution

High

Aquapharm Q2 EBITDA ₹42 Cr vs prior ₹75 Cr quarterly target (56% miss). Target formally deferred. New CEO analyzing business model.

Margin pressure

Medium

Shipping, freight, power costs elevated. Crude volatility impacting feedstock costs. Customer caution reducing operating leverage. NPM only 3.0%.

Specialty Carbon Black

Medium

Specialty CB capacity ~75 tonnes. Feedstock availability is a critical bottleneck. Mundra Line expansion at risk if sourcing doesn't improve.

Management

Score 7/10. Candid on headwinds (geopolitical, inventory destocking, freight/power cost inflation). Transparent on Aquapharm challenge and target deferral. Good strategy articulation. Some vagueness on Aquapharm remediation and H2 recovery specifics. Pricing discipline delivered (14% revenue, 20% PAT YoY). Volume management disciplined but demand-driven. Aquapharm execution lagging significantly. Cost program (Alchemy) on track.

What to watch next
  • 1 · Q3-Q4 FY27

    Customer inventory normalization; ordering patterns improve on price clarity

  • 2 · H2 FY27

    Russian CBFS supply constraints firm pricing; China coal tar price inflation supports spreads

  • 3 · FY28

    U.S./Europe warehouse infrastructure yields export volume growth

Long-term structural tailwinds (tyre expansion, battery materials) are real but require flawless H2 delivery and margin stabilization.

Informational and educational content only. Not investment advice.